GlassScriptPhysician profile
Jason D Hoskins
NPI 1588961163
$3,163.57
in general payments reported to CMS, 2019-2025
21 companies · $576 in 2025
The $576 reported for 2025 was more than what a typical Vascular & Interventional Radiology provider received nationally (typical 2025 total: $537).
See the full distribution for Vascular & Interventional Radiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,201 · 2020: $189 · 2021: $170 · 2022: $474 · 2023: $239 · 2024: $314 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocompatibles, INC. | $1,040.38 | 2019 | |
| Boston Scientific Corporation | $573.08 | 2019-2024 | Ekosonic, Ranger, Embold Fibered |
| Inari Medical, INC. | $364.28 | 2021-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Stryker Corporation | $304.45 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit, Artix Mt |
| Sirtex Medical INC | $223.44 | 2024 | Sir-Spheres Microspheres |
| Penumbra, INC. | $201.30 | 2025 | Indigo System, Penumbra System |
| Astrazeneca Pharmaceuticals LP | $97.86 | 2022-2023 | Imfinzi, Tagrisso |
| Shockwave Medical, INC | $56.81 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Ipsen Biopharmaceuticals, INC | $41.68 | 2020-2022 | |
| Reflow Medical INC | $30.79 | 2025 | |
| Daiichi Sankyo INC. | $27.76 | 2022 | |
| Terumo Medical Corporation | $24.54 | 2025 | Hydropearl |
| Cook Medical LLC | $24.48 | 2023 | Cook |
| Genzyme Corporation | $24.02 | 2021 | |
| Celgene Corporation | $21.51 | 2023 | Opdualag |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.21 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.65 | 2022 | |
| Medtronic USA, INC. | $20.24 | 2020 | |
| Aveo Pharmaceuticals, INC. | $19.40 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.00 | 2019 | |
| Incyte Corporation | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Hoskins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.